1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
(3)Capsule
(4)Injection
(5)Liquid Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-3-094
GLP-1 CAS 87805-34-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide GLP-1 Injections, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html
Lilly issues a public warning: there is a safety risk associated with the mixture of Tilapide and Vitamin B12
On March 12, 2026, Lilly issued a public warning regarding the potential safety risks associated with the mixture of tirzepatide and vitamin B12.
Adhering to its commitment to patient safety, Lilly has conducted testing on products sold in the US market that contain a combination of tiltrotide and B12 (sometimes referred to as methylcobalamin, hydroxocobalamin, or cyanocobalamin). It was found through testing that the chemical reaction between tilpotide and B12 produces significant impurities.
The impurities generated by the interaction between B12 and tiltrotide are concerning, as there is currently no knowledge about its short-term and long-term effects in the human body, potential effects on drug binding GLP-1 and GIP receptors, toxicity, immune response, as well as absorption, distribution, metabolism, and excretion pathways.
Tilpotide has never been studied in combination with B12, and the compounding pharmacies that produce these compound drugs do not need to monitor or report adverse events, so the risks faced by patients are completely unknown. People who use tilbopeptide-B12 products from compounding pharmacies, telemedicine companies, medical spas, or other channels should be aware that they may be using products with unknown risks and potential hazards. Lilly has reported the above findings to the US FDA and recommends that patients using such untested products contact a doctor for consultation and discussion of alternative treatment options.
For pet diabetes, Yinnuo Pharmaceutical's ultra long-acting GLP-1 applied for clinical application
On February 4, 2026, Yinnuo Pharmaceutical announced that the application for the clinical trial of its core product, Esupagludide α, for the treatment of pet diabetes, as a new veterinary drug, had been officially accepted by the Ministry of Agriculture and was expected to start the phase I clinical trial in the quarter of 2026.
Esupagllutide α is a new generation of human super long-acting GLP-1 drug in the world. Its core advantage lies in the use of genetic engineering recombinant protein technology to form a dual molecular structure through unique natural hinge connection and lgG2 fusion protein, which makes it have a strong affinity for GLP-1 receptor, and is more slowly degraded by enzymes and filtered by kidneys in vivo. It can achieve an average half-life of 204 hours in patients with type 2 diabetes. It supports subcutaneous injection every 1-2 weeks, giving consideration to strong efficacy and medication convenience,
In January 2025, esupagglutide α was approved to be marketed in China for the treatment of adult type 2 diabetes, including single drug and patients who still have poor blood glucose control after receiving metformin treatment, and subcutaneous injection was given once a week. In the same year, the product was successfully included in the medical insurance catalog through negotiations, and its weight loss indications were also being applied for.
Eli Lilly 2025: Tenpo Peptide Surges $36.5 Billion
On February 4, 2026, Eli Lilly announced its full year financial report for 2025, with a total revenue of $65.179 billion (+44%) for the year. The annual R&D expenditure was 13.337 billion US dollars (+21%), accounting for 20% of the total revenue From a regional distribution perspective, in 2025, the US market revenue will be $43.481 billion (+43%), the European market revenue will be $11.558 billion (+62%), the Japanese market revenue will be $2.132 billion (+16%), the Chinese market revenue will be $1.951 billion (+18%), and the remaining market revenue will be $6.057 billion (+42%). From the perspective of treatment, Lilly currently focuses on four major disease areas: diabetes, tumor, immunity and nerve.
Diabetes is the core business of Lilly. As the world's most eye-catching drug, the GLP-1R/GIPR agonist Tilpodide's glucose reducing Mouniaro and weight-loss Zepbound show strong gold absorption ability. Mouniaro's annual sales reached $22.965 billion (+99%), becoming the first super blockbuster product with annual revenue exceeding $20 billion in the company's history. Zepbound's annual revenue also reached $13.542 billion (+175%). The combined contribution of these two products alone exceeds $36.5 billion.
The core product Verzenio (CDK4/6 inhibitor) in the field of oncology has achieved annual sales of 5.723 billion US dollars (+8%). Eli Lilly will promote multiple clinical trials of oral GLP-1R agonist Orforglipron in 2026 and advance the key regulatory phase of Retatrutide (GLP-1R/GIPR/GCGR agonist).